ArticleJournal of artificial organs : the official journal of the Japanese Society for Artificial Organs2026
Post-transplant predictors of mortality and primary graft dysfunction in lung transplant recipients bridged with veno-venous extracorporeal membrane oxygenation.
Article in Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeVeno-venous extracorporeal membrane oxygenation (VV-ECMO) is increasingly used to bridge critically ill candidates to lung transplantation, with reported outcomes approaching those of non-ECMO recipients. However, factors associated with early mortality in this high-risk subpopulation remain incompletely defined, particularly when postoperative complications occur after transplantation and may introduce time-dependent bias. We aimed to explore factors associated with 1-year survival among VV-ECMO-bridged lung transplant recipients.
methodsWe performed a single-center retrospective cohort study of adult lung transplant recipients bridged with preoperative VV-ECMO between January 2018 and May 2024. The primary endpoint was 1-year overall survival. Associations with primary graft dysfunction grade 3 were assessed using logistic regression. Because postoperative complications occurred after transplantation, landmark Kaplan-Meier analyses were performed to explore their associations with subsequent survival while reducing immortal time bias.
resultsForty recipients were included, and 1-year mortality was 20% (8/40). Primary graft dysfunction grade 3 occurred in 16 recipients (40%). Higher pretransplant creatinine and lower albumin showed suggestive associations with primary graft dysfunction grade 3, although these associations did not reach statistical significance in multivariable analysis. In conventional Cox analyses, postoperative pulmonary embolism, dialysis/renal replacement therapy, and antibody-mediated rejection were associated with mortality; however, these findings should be interpreted cautiously because these postoperative complications were time-dependent and the number of deaths was limited. Landmark analyses showed that dialysis/renal replacement therapy by POD30 was associated with worse subsequent survival, whereas the associations for pulmonary embolism by POD90 and antibody-mediated rejection by POD90 were limited by sparse events.
conclusionsIn this single-center cohort of VV-ECMO-bridged lung transplant recipients, postoperative complications including pulmonary embolism, dialysis/renal replacement therapy, and antibody-mediated rejection were associated with mortality in exploratory analyses, with dialysis showing the most consistent association in landmark analysis. Given the small sample size and limited number of events, these findings should be interpreted as hypothesis-generating and require validation in larger multicenter cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.